VCNX(Delisted)
Vaccinex·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 0
Bearish signal 1
Significant Revenue Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VCNX
Vaccinex, Inc.
A biotechnology company that develops antibody-based therapies for cancer and neurodegenerative diseases
1895 Mount Hope Avenue, Rochester, New York 14620
--
Vaccinex, Inc., was incorporated in April 2001 under the laws of the State of Delaware. The company is a clinical-stage biotechnology company dedicated to the discovery and development of targeted biotherapeutic drugs to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune diseases. The company is leveraging their SEMA 4D antibody platform and their extensive knowledge in SEMA 4D biology to develop the lead product candidate pepinemab (also known as VX 15/2503). The company focuses on the development of pepinemab for the treatment of certain cancer indications, particularly head and neck squamous cell carcinoma, pancreatic cancer and PDAC, as well as neurodegenerative diseases, including Huntington's disease and Alzheimer's disease.
Company Financials
EPS
VCNX has released its 2023 Q3 earnings. EPS was reported at -1.09, versus the expected 0, missing expectations. The chart below visualizes how VCNX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VCNX has released its 2024 Q3 earnings report, with revenue of 52.00K, reflecting a YoY change of 160.00%, and net profit of -5.73M, showing a YoY change of -16.69%. The Sankey diagram below clearly presents VCNX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
